<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03900026</url>
  </required_header>
  <id_info>
    <org_study_id>NEWTON CABG (Cardiolink-007)</org_study_id>
    <nct_id>NCT03900026</nct_id>
  </id_info>
  <brief_title>Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery</brief_title>
  <acronym>NEWTON-CABG</acronym>
  <official_title>A Randomized Trial of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery (NEWTON-CABG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Applied Health Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if evolocumab added to regular statin therapy&#xD;
      improves vein graft patency after coronary artery bypass graft (CABG) surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery bypass graft (CABG) surgery is a procedure in which an artery or vein from&#xD;
      the body is grafted to a critically narrowed coronary artery to restore flow of oxygenated&#xD;
      blood to the heart. Statins are frequently prescribed after CABG surgery in order to lower&#xD;
      LDL cholesterol levels and reduce the chances of coronary artery obstruction recurring.&#xD;
      Despite this preventive measure, new vein grafts do end up becoming blocked in a significant&#xD;
      proportion of patients. Evolocumab (Repatha®) is a recently approved medication that has been&#xD;
      shown to effectively lower LDL cholesterol levels in the blood.&#xD;
&#xD;
      NEWTON-CABG is an investigator-initiated multicenter, double-blind, randomized,&#xD;
      placebo-controlled, parallel group study of evolocumab [140mg administered subcutaneously&#xD;
      (SC) every two weeks (Q2W)] added to statin therapy for 24 months postoperatively in a broad&#xD;
      population of patients undergoing CABG surgery. Eligible subjects will be randomized to&#xD;
      receive evolocumab or placebo within 21 days of index CABG. Prior to randomization,&#xD;
      post-operative patients will be on moderate or high intensity statin therapy (atorvastatin&#xD;
      40-80mg, rosuvastatin 20-40mg or simvastatin 40mg daily unless another statin/dose or&#xD;
      non-statin alternative is clinically justified). A CTAngiogram will be conducted at 24 months&#xD;
      following CABG. Routine study visits will be done 3, 6, 12, 18 and 24 months post-surgery.&#xD;
&#xD;
      This study is supported by Amgen Inc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, double-blind, randomized, placebo-controlled, parallel group study of evolocumab.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Saphenous vein graft disease rate (VGDR)</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Saphenous vein graft disease rate (VGDR) is defined as the proportion of vein grafts with significant stenosis or total occlusion (≥50%) on 64-slice (or greater) cardiac CT angiography (CTA) or clinically indicated coronary angiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with at least 1 vein graft totally (100%) occluded.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Proportion of patients who have at least 1 totally (100%) occluded vein graft at 24 months post CABG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of vein grafts which are totally (100%) occluded grafts.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Percentage of vein grafts that are totally (100%) occluded at 24 months post CABG.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Composite rate of fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, cardiovascular death, coronary heart disease death, repeat coronary revascularization</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>composite rate of occurrence of the above mentioned clinical outcomes at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of fatal and non-fatal myocardial infarction.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of fatal and non-fatal stroke.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of cardiovascular death.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of coronary heart disease death.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of repeat coronary revascularization.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of all-cause mortality.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Proportion of patients who have died at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of total vein graft patency at 24 months.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Rate of total vein graft patency defined as 1-VGDR at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients free of vein graft disease at 24 months.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Percentage of patients who are free of vein graft disease at 24 months defined as having no vein grafts with ≥ 50% stenosis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vein graft plaque volume.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Volume of vein graft plaque at 24 months post CABG.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">766</enrollment>
  <condition>Coronary Artery Bypass Graft Surgery</condition>
  <condition>Atherosclerosis</condition>
  <condition>Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive subcutaneous injections of the placebo Q2W (every 2 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneous injections of 140mg of evolocumab Q2W (every two weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>REPATHA (evolocumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); it will be administered via subcutaneous injection</description>
    <arm_group_label>Evolocumab Treatment</arm_group_label>
    <other_name>Repatha®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo cartridges will contain vehicle only; placebo will be administered via subcutaneous injection.</description>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria - To be considered eligible for participation in this study, a&#xD;
        participant must satisfy each of the following criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Scheduled to undergo coronary artery bypass graft (CABG) surgery (with or without&#xD;
             cardiopulmonary bypass (CPB); with or without single valve repair/replacement)&#xD;
&#xD;
          3. CABG procedure included/planned to include at least two saphenous vein grafts&#xD;
&#xD;
          4. CABG procedure occurred within the past 21 days, or is planned within the next 60 days&#xD;
&#xD;
          5. On a moderate to high intensity statin therapy (defined as atorvastatin 40-80mg daily,&#xD;
             rosuvastatin 20-40mg or simvastatin 40mg daily) unless a lower dose, or another statin&#xD;
             or non-statin therapy is clinically justified&#xD;
&#xD;
        Exclusion Criteria - A participant will be ineligible for participation in this study if he&#xD;
        or she satisfies any one or more of the following criteria:&#xD;
&#xD;
          1. Patients in whom additional lowering of LDL-C with evolocumab is deemed to be&#xD;
             clinically inappropriate&#xD;
&#xD;
          2. Allergy to contrast dye&#xD;
&#xD;
          3. Known severe hepatic impairment (Childs-Pugh, Class C).&#xD;
&#xD;
          4. Known renal disease with estimated glomerular filtration rate (eGFR) &lt; 30&#xD;
             mL/min/1.73m2&#xD;
&#xD;
          5. Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow)&#xD;
&#xD;
          6. Use of cholesterylester transfer protein (CETP) inhibition treatment within 12 months&#xD;
             prior to randomization.&#xD;
&#xD;
          7. Current, prior within past year, or known planned use of PCSK9 inhibition treatment&#xD;
&#xD;
          8. Severe cardiovascular or concomitant non-cardiovascular disease that is expected to&#xD;
             reduce life expectancy to less than 2 years&#xD;
&#xD;
          9. Major active infection, or major hematologic, renal, respiratory, metabolic,&#xD;
             gastrointestinal or endocrine dysfunction&#xD;
&#xD;
         10. Women who are pregnant or breastfeeding&#xD;
&#xD;
         11. Women of child bearing potential who are unwilling to use proper family planning or&#xD;
             birth control methods to avoid pregnancy. Women are considered post-menopausal and not&#xD;
             of childbearing potential after 12 months of natural (spontaneous) amenorrhea or have&#xD;
             had a surgical procedure such as hysterectomy which makes pregnancy impossible.&#xD;
&#xD;
         12. Known intolerance or allergy to evolocumab or other PCSK9 inhibitors.&#xD;
&#xD;
         13. Currently taking simvastatin &gt;40mg/day, niacin or bile acid sequestrants&#xD;
&#xD;
         14. Known latex allergy&#xD;
&#xD;
         15. Inability to comply with protocol-required study visits or procedures, including&#xD;
             administration of study drug&#xD;
&#xD;
         16. Known history of cancer within the past 5 years (except for carcinoma in-situ of the&#xD;
             cervix, stage 1 prostate cancer or adequately treated non-melanoma carcinomas of the&#xD;
             skin)&#xD;
&#xD;
         17. Participation in another investigational device or drug study which is likely to&#xD;
             affect the primary outcome, within 30 days of planned initiation of study drug&#xD;
&#xD;
         18. NYHA class IV&#xD;
&#xD;
         19. Pacemaker or other implantable device implanted within 30 days prior to screening&#xD;
&#xD;
        Additional postoperative exclusion criteria:&#xD;
&#xD;
          1. Received only &lt;2 vein grafts&#xD;
&#xD;
          2. Major peri-operative complications following CABG surgery (e.g. stroke, MI, renal&#xD;
             failure requiring dialysis, or postoperative ICU stay &gt; 5 days) prior to randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Mazer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Subodh Verma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Leiter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danusha Nandamalavan</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>77038</phone_ext>
    <email>NandamalavaD@smh.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Kunze</last_name>
      <phone>203-737-2150</phone>
      <email>kim.kunze@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Umer Darr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Burns</last_name>
      <phone>904-576-0166</phone>
      <email>heathburns@encoredocs.com</email>
    </contact>
    <investigator>
      <last_name>Michael Koren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsey Gallant</last_name>
      <email>WIGHTA@mmc.org</email>
    </contact>
    <contact_backup>
      <phone>207-662-1489</phone>
    </contact_backup>
    <investigator>
      <last_name>Robert Kramer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maliha Muneer</last_name>
      <phone>780-407-8614</phone>
      <email>muneer@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Andrew Shaw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Mullen</last_name>
      <phone>905.521.2100</phone>
      <phone_ext>44342</phone_ext>
      <email>Courtney.Mullen@phri.ca</email>
    </contact>
    <investigator>
      <last_name>Richard Whitlock</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah DuMerton</last_name>
      <phone>613-549-6666</phone>
      <phone_ext>3224</phone_ext>
      <email>Deborah.DuMerton@kingstonhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Tarit Saha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shira Brodutch</last_name>
      <phone>416-864-6060</phone>
      <phone_ext>49419</phone_ext>
      <email>Shira.Brodutch@unityhealth.to</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo Tremblay</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3797</phone_ext>
      <email>hugo.tremblay@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Francois Dagenais</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Maier</last_name>
      <email>Karen.Maier@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Alex Gregory</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Bypass Surgery</keyword>
  <keyword>CABG</keyword>
  <keyword>Saphenous Vein Graft</keyword>
  <keyword>Evolocumab</keyword>
  <keyword>Repatha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

